BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo by Lee, Edward B. et al.
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
Y
 
©
 
 The Rockefeller University Press $8.00
The Journal of Cell Biology, Vol. 168, No. 2, January 17, 2005 291–302
http://www.jcb.org/cgi/doi/10.1083/jcb.200407070
 
JCB: ARTICLE
 
JCB 291
 
BACE overexpression alters the subcellular processing 
of APP and inhibits A
 
 
 
 deposition in vivo
 
Edward B. Lee,
 
1
 
 Bin Zhang,
 
1
 
 Kangning Liu,
 
1
 
 Eric A. Greenbaum,
 
1
 
 Robert W. Doms,
 
2
 
 John Q. Trojanowski,
 
1,3
 
 
and Virginia M.-Y. Lee
 
1,3
 
1
 
The Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, 
 
2
 
Department of Microbiology, and 
 
3
 
Institute on Aging, 
University of Pennsylvania School of Medicine, Philadelphia, PA 19104
 
ntroducing mutations within the amyloid precursor
protein (APP) that affect 
 
 
 
- and 
 
 
 
-secretase cleavages
results in amyloid plaque formation in vivo. However,
the relationship between 
 
 
 
-amyloid deposition and the
subcellular site of A
 
 
 
 production is unknown. To deter-
mine the effect of increasing 
 
 
 
-secretase (BACE) activity
on A
 
 
 
 deposition, we generated transgenic mice overex-
pressing human BACE. Although modest overexpression
enhanced amyloid deposition, high BACE overexpression
inhibited amyloid formation despite increased 
 
 
 
-cleavage
I
 
of APP. However, high BACE expression shifted the
subcellular location of APP cleavage to the neuronal peri-
karya early in the secretory pathway. These results sug-
gest that the production, clearance, and aggregation of
A
 
 
 
 peptides are highly dependent on the speciﬁc neu-
ronal subcellular domain wherein A
 
 
 
 is generated and
highlight the importance of perikaryal versus axonal APP
proteolysis in the development of A
 
 
 
 amyloid pathology
in Alzheimer’s disease.
 
Introduction
 
Although the characteristic lesions of Alzheimer’s disease (AD),
amyloid plaques and neurofibrillary tangles, have been recog-
nized for almost a century, the mechanisms whereby these de-
posits accumulate in vivo are still largely unknown. A
 
 
 
 peptides
are the major constituent of amyloid plaques and are produced
by sequential proteolysis of amyloid precursor protein (APP) by
 
 
 
- and 
 
 
 
-secretase (Wilson et al., 1999). Amyloid plaques are
formed in vivo upon overexpressing APP mutations that shift
 
 
 
-cleavage toward the production of the more amyloidogenic
42–amino acid variant of A
 
 
 
 (A
 
 
 
42
 
; Games et al., 1995), or by
direct manipulation of 
 
 
 
-secretase by introducing mutations
within presenilin, a subunit of the multimeric 
 
 
 
-secretase
complex (Borchelt et al., 1997). APP mutations that increase
 
 
 
-cleavage also result in A
 
 
 
 deposition (Hsiao et al., 1996).
An aspartyl protease, BACE, is the major 
 
 
 
-secretase
(Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin
et al., 2000). BACE cleaves either at Asp1 or Glu11 (numbering
relative to the first amino acid in A
 
 
 
) to release NH
 
2
 
-terminal
ectodomains referred to as sAPP
 
 
 
 and sAPP
 
  
 
, respectively
(Fig. 2 A). The remaining membrane-bound COOH-terminal
APP fragments are then cleaved by 
 
 
 
-secretase to produce
full-length A
 
 
 
1-40/42
 
 or the NH
 
2
 
-terminally truncated A
 
 
 
11-40/42
 
.
BACE overexpression in neuronal (E.B. Lee et al., 2003) and
nonneuronal cells (Vassar et al., 1999; Huse et al., 2002; Liu
et al., 2002) increases A
 
 
 
 generation, whereas genetic abla-
tion of BACE eliminates A
 
 
 
 production (Cai et al., 2001;
Luo et al., 2001).
Less is known about the significance of the subcellular
localization of APP processing with respect to amyloid plaque
formation. In addition to the ER and the Golgi apparatus, APP
is enriched in axons and presynaptic terminals (Schubert et al.,
1991; Ferreira et al., 1993). Although A
 
 
 
 is generated in several
different organelles in vitro (Wilson et al., 1999), the subcellular
site of A
 
 
 
 generation in vivo is more difficult to assess. How-
ever, studies indicate that APP undergoes kinesin I–dependent
vesicular fast axonal transport (Koo et al., 1990; Ferreira et al.,
1993) and that APP proteolysis may occur within axonal or
presynaptic vesicles (Buxbaum et al., 1998). Furthermore,
synaptic activity increases A
 
 
 
 secretion, indicating that the
presynaptic  terminal is an important regulatory site for A
 
 
 
generation (Kamenetz et al., 2003). Finally, ablation of the per-
forant pathway in APP transgenic (Tg) mice decreases amyloid
plaque deposition in the hippocampus, suggesting that synap-
tic A
 
 
 
 contributes to plaque formation (Lazarov et al., 2002;
Sheng et al., 2002).
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A priori, increased BACE activity is expected to increase
A
 
 
 
 pathology. Indeed, modest BACE overexpression in mice
increases steady-state A
 
 
 
 levels (Bodendorf et al., 2002). How-
ever, we discovered that high BACE overexpression paradoxi-
cally decreased A
 
 
 
 deposition despite enhanced 
 
 
 
-cleavage
of APP. Furthermore, we found that BACE overexpression
altered the subcellular localization of BACE cleavage by in-
creasing 
 
 
 
-cleavage early in the secretory pathway, thereby de-
pleting APP destined for axonal transport. These unexpected
findings underscore the importance of the subcellular site of
A
 
 
 
 generation in the pathogenesis of AD.
 
Results
 
Generation of BACE Tg mice
 
To determine whether increased BACE activity affects A
 
 
 
deposition in vivo, we produced three lines of Tg mice express-
ing different levels of human BACE driven by the prion protein
(PrP) promoter (Fig. 1 A), determined by immunoblotting of
cortical, hippocampal, and cerebellar lysates (Fig. 1 B). Line
30 expressed the lowest amount of BACE, followed by lines 34
and 8 (hereafter named BACE-L, BACE-M, and BACE-H,
respectively), expressing BACE 
 
 
 
7-, 10-, and 20-fold over en-
dogenous levels (Fig. 1 C and Fig. 2 B). Increased BACE ex-
pression (Fig. 1 D) was also noted by immunohistochemistry
which, in addition to neuronal cell bodies, demonstrated BACE
staining in axons and synaptic elements such as the mossy fiber
terminals of the hippocampus, puncta within the granule cell
layer of the cerebellum, and neuropil within the spinal cord
(Fig. 1 D, g–i), suggesting that BACE is subject to anterograde
axonal transport.
 
APP processing in BACE Tg mice
 
To determine the effects of BACE expression on APP process-
ing and A
 
 
 
 production in vivo, we crossed BACE Tg lines with
the tg2576 mouse model overexpressing APPswe (Hsiao et al.,
1996), and APP processing in these bigenic mice was studied
by following the fate of the APP fragments shown in Fig. 2 A.
BACE expression was similar in single BACE and bigenic APPx-
BACE mice (Fig. 2 B). However, BACE overexpression al-
tered the banding pattern of total APP (i.e., full-length APP as
well as secreted APP ectodomains), apparent for both exoge-
nous (light exposure) and endogenous (dark exposure) APP. To
better understand the effect of BACE expression on APP pro-
Figure 1. Generation of Tg mice overexpressing human BACE. (A) Schematic of the expression cassette used to generate PrP-BACE mice, containing the
human BACE cDNA flanked by the 5  UTR of the murine PrP gene containing an intron, and the 3  UTR of the PrP gene. (B) BACE expression in Tg mice.
RIPA lysates from the cortex, hippocampus, and cerebellum were immunoblotted for BACE using an antibody against the COOH terminus of human
BACE. Three Tg lines (n   3; shown are mice at 14–16 mo) were analyzed with low (30), medium (34), and high (8) expression. (C) BACE expression
relative to non-Tg mice. Cortical RIPA lysates were diluted as indicated before immunoblotting for BACE using a polyclonal antisera against the entire NH2-
terminal ectodomain of BACE. BACE-L, -M, and -H mice overexpress  7-, 10-, and 20-fold more BACE than non-Tg mice (n   3 per genotype). No age-
dependent changes in BACE expression have been observed (up to 20 mo). (D) Regional expression of BACE. Immunohistochemistry using BACE-N1
demonstrates increased immunoreactivity in BACE overexpressing mice. Representative images are shown of the cortex, striatum, cerebellum, brainstem,
and spinal cord. Higher magnification shows staining of mossy fiber terminals, the granule cell layer of the cerebellum, and the dorsal spinal cord.
Sections from APP (a–c) and BACE-H (d–i) mice are shown. Black arrowheads demonstrate synaptic/axonal staining, whereas white arrowheads show
Purkinje cells. Wild-type/APP or BACE/BACExAPP mice showed no differences in staining (n   2 per genotype). Similar staining was observed with a
polyclonal antibody raised against the COOH terminus of BACE and polyclonal antibodies raised against the ectodomain of BACE. Bars: (a and d) 500  m;
(b and e) 500  m; (c and f) 250  m; (g) 150  m; (h) 25  m; (i)100  m. 
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teolysis, immunoblots specific for different APP species were
performed. Full-length APP, predominantly the 
 
N
 
- and 
 
O
 
-gly-
cosylated forms of APP detected by 4G8 (anti-A
 
 
 
17-24
 
), was re-
duced by BACE overexpression, which is consistent with in-
creased APP proteolysis. This decrease in full-length APP
was paralleled by an increase in BACE-derived sAPP species
(Fig. 2 B) including sAPP
 
 
 
swe (generated from exogenous
APPswe), sAPP
 
 
 
 (generated from endogenous APP), and
sAPP
 
  
 
 (produced by cleavage at the Glu11 cleavage site).
Therefore, BACE overexpression resulted in increased 
 
 
 
-cleav-
age of both exogenous and endogenous APP.
Increased BACE activity also altered steady-state levels
of COOH-terminal APP fragments (Fig. 2 C). In monogenic
BACE mice, BACE-derived COOH-terminal APP fragments,
predominantly C89, were increased relative to wild-type mice,
which is consistent with the preferential cleavage of rodent
APP at position 11 within A
 
 
 
 (Wang et al., 1996; Gouras et al.,
1998; Cai et al., 2001). In APP overexpressing mice, five dis-
tinct bands corresponding to APP COOH-terminal fragments
were apparent (Fig. 2 C). Several of these bands correspond to
phosphorylated COOH-terminal APP fragments as dephos-
phorylation with alkaline phosphatase collapsed the five bands
into three bands corresponding to C99, C89, and C83 (Fig. 2 C,
left vs. right). As expected, BACE overexpression increased
steady-state levels of C99 and C89, whereas 
 
 
 
-secretase–
derived C83 was decreased, which is consistent with a subcel-
lular competition between 
 
 
 
- and 
 
 
 
-cleavage (Skovronsky et
al., 2000). Interestingly, despite an overall increase in C99,
BACE overexpression decreased the amount of phospho-C99
by 
 
 
 
50–60% in APPxBACE-L and APPxBACE-M mice and
over 80% in APPxBACE-H mice.
 
Decreased steady-state A
 
 
 
 due to BACE 
overexpression
 
We hypothesized that the increase in C99 would be paralleled
by an increase in A
 
 
 
. Surprisingly, ELISA quantification of
steady-state A
 
 
 
 from young mice (5–7 mo) indicated that high
BACE expression paradoxically decreased full-length A
 
 
 
 pro-
duction (Fig. 3 A). Although very high BACE overexpression
in cell culture models results in cleavage at positions 11 and 34
within A
 
 
 
, immunoprecipitation of brain lysates with 4G8, al-
beit less quantitative than ELISA methods, failed to detect any
peptides other than full-length A
 
 
 
 and p3 (Fig. 3 B). Thus,
truncated A
 
 
 
 peptides such as A
 
 
 
1-34
 
 and A
 
 
 
11-40/42
 
 are pro-
Figure 2. Increase in  -cleavage due to BACE overexpression. (A) Diagram of sequential APP processing by BACE,  -secretase, and  -secretase.
(B) Steady-state levels of BACE and APP in monogenic and bigenic mice. RIPA lysates from wild-type, BACE, APP, and APPxBACE Tg mice (n   3–5 per
genotype) were immunoblotted for BACE and several APP species. BACE was probed with 84 (anti-BACE ectodomain). Total APP including full-length APP
and all sAPP species was probed with Karen (anti–NH2 terminal APP). Two exposures are shown for optimal visualization of exogenous (light) and endogenous
(dark) APP. Full-length APP was probed with 4G8. sAPP swe, sAPP , and sAPP   were probed with end-specific antibodies 54, C5A4 and C10A4,
respectively. An immunoblot for  -tubulin is shown to demonstrate equal loading in all lanes. (C) Steady-state levels of COOH-terminal APP fragments in
monogenic and bigenic mice. Whole brain RIPA lysates from wild-type, BACE, APP, and APPxBACE Tg mice were immunoprecipitated and immunoblotted
with 5685 to recover COOH-terminal APP fragments. Select immunoprecipitates were dephosphorylated (right) before electrophoresis. White lines indicate
that intervening lanes have been spliced out.JCB • VOLUME 168 • NUMBER 2 • 2005 294
duced at very low levels relative to full-length A , or are rap-
idly degraded in vivo. To confirm the lack of NH2-terminally
truncated A  peptides, additional ELISA’s were performed to
detect either full-length A 1-40/42 or total A x-40/42 (Fig. 3, C and
D). Equivalent amounts of A 1-40/42 and A x-40/42 were detected
suggesting that NH2-terminally truncated A  species were pres-
ent at very low levels. These results were corroborated by the
near absence of truncated A  in amyloid deposits of older Tg
mice (Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200407070/DC1).
Decreased A  deposition due to BACE 
overexpression
Monogenic BACE mice showed no evidence of A  deposition
(unpublished data). Therefore, to determine the impact of
BACE overexpression on A  deposition, we evaluated APP
and APPxBACE mice at 14–16 mo old for amyloid plaque pa-
thology. As shown by thioflavin S staining, APPxBACE-L
mice exhibited increased amyloid plaque formation within the
cortex (Fig. 4 A). However, higher levels of BACE expression
dramatically decreased thioflavin S positive cortical deposi-
tion of A  amyloid. Essentially identical results were obtained
by performing immunohistochemistry using NAB228 (anti-
A 1-11) or 4G8 (anti-A 17-24), indicating that the observed de-
crease was not due to a shift from fibrillar to diffuse A  depos-
its. Unlike cortical amyloid plaques, hippocampal A  depos-
its were diminished even in the BACE-L mice, whereas the
BACE-M and BACE-H lines showed virtually no hippocampal
A  deposits. Quantification of amyloid burden showed that
APPxBACE-L mice displayed a significantly higher amyloid
burden within the somatosensory cortex with a corresponding
decrease in amyloid burden in the hippocampus (Fig. 4, B–D).
Higher BACE expression inhibited A  deposition within both
the cortex and the hippocampus.
We confirmed our morphological results by quantitative
A  ELISA after sequential extraction of brain regions with
RIPA buffer followed by formic acid (FA) to obtain detergent
soluble and insoluble fractions. Consistent with the histological
results, cortical A  was slightly higher in APPxBACE-L mice in
both soluble and insoluble fractions when compared with mono-
genic APP mice (Fig. 5, A and B), whereas higher BACE ex-
pression inhibited cortical A  accumulation. BACE overexpres-
sion also decreased hippocampal A  levels in both soluble and
insoluble fractions for all three BACE overexpressing lines (Fig.
5, C and D). A  levels were very low in the cerebellum, which is
consistent with the lack of cerebellar amyloid plaques (Fig. 5, E
and F). Thus, although a modest increase in BACE activity, es-
pecially in the neocortex, enhanced the deposition of A , larger
increases in BACE activity had the unexpected, opposite result.
Biochemical markers of APP maturation 
in APPxBACE axons
Two findings pointed to diminished axonal transport of APP as
the cause for the unexpected discrepancy between increased
C99 and decreased A . First, the dissociation between cortical
and hippocampal amyloid in APPxBACE-L mice suggested
that BACE overexpression altered A  deposition via a mecha-
nism related to the spatial location of APP processing. Second,
phospho-C99 is the only BACE-derived APP species that was
decreased in a dose-dependent manner upon BACE overex-
pression (Fig. 2 C and Fig. 6 A). This suggested that phospho-
C99 may be the precursor to A  peptides that eventually de-
Figure 3. BACE overexpression decreases
steady-state A  levels. (A) Dose-dependent
decrease in steady-state A . Steady-state A 
levels from RIPA cortical lysates (APP, n   5;
APPxBACE, n   3 per genotype, 5–7 mo old)
were quantified by Ban50-BA27/BC05 sand-
wich ELISA for full-length A 40 and A 42.
(ANOVA, P   0.0001; Bonferroni’s post-hoc
relative to APP, *P   0.05, ***P   0.001).
(B) RIPA lysates were subject to immunoprecipi-
tation with 4G8, followed by electrophoresis
on a 10/16.5% Tris-tricine gel. Immunoblotting
with 4G8 demonstrates the presence of full-
length A  and p3 with little NH2- or COOH-
terminally truncated A  variants (n   2 per ge-
notype). An overexposure of the immunoblot is
shown to demonstrate the presence of p3 and
the absence of other truncated A  peptides.
White lines indicate that intervening lanes have
been spliced out. (C) Steady-state A  levels
from RIPA cortical lysates (n   3–5 mice per
genotype, 5–7 mo old) were quantified by JRF/
c40-A N or JRF/c42-A N ELISA for full-length
A 40 and A 42. (ANOVA, P   0.0019; Bonfer-
roni’s post-hoc relative to APP, **P   0.01).
(D) Steady-state A  levels from RIPA cortical
lysates (n   3–5 mice per genotype, 5–7 mo
old) were quantified by JRF/c40-m266 or JRF/
c42-m266 ELISA for total (full-length and NH2-
terminally truncated) A 40 and A 42. (ANOVA,
P   0.0015; Bonferroni’s post-hoc relative to
APP, ***P   0.001).PERIKARYAL BACE CLEAVAGE INHIBITS A  DEPOSITION • LEE ET AL. 295
posit into amyloid plaques, which is consistent with an increase
in phospho-C99 in AD brains (M.S. Lee et al., 2003). The lo-
calization of phospho-APP in post-Golgi vesicles within den-
drites and axons (Ando et al., 1999; Iijima et al., 2000; M.S.
Lee et al., 2003) suggests that APP phosphorylation occurs late
in the secretory pathway. Therefore, we hypothesized that en-
hanced BACE expression leads to increased APP cleavage
early in the secretory pathway, depleting APP before its trans-
port to the presynaptic terminal.
If BACE cleavage occurs early in the secretory pathway,
markers of APP maturation should be reduced in APPxBACE
mice. Indeed, N- and O-glycosylated APP and phospho-C99
were both reduced upon BACE overexpression (Fig. 2). To
better assess the levels of phospho-APP, we generated an anti–
phospho-APP-threonine 668 (PhAT), phosphorylation-spe-
cific antibody. Although antisera 5685 immunoprecipitated
both nonphosphorylated and phosphorylated C99, PhAT recog-
nized only the slower migrating phospho-C99 (Fig. 6 A). As
predicted, we observed a marked decrease in phospho-Thr668-
C99 in cortical extracts derived from APPxBACE mice. Fur-
thermore, phospho-APP was recovered from monogenic APP
mice but not bigenic APPxBACE mice (Fig. 6 A). We also
found that only fully glycosylated APP is phosphorylated at
Thr668 corroborating reports that APP phosphorylation occurs
late in the secretory pathway after acquisition of O-linked car-
bohydrates within the Golgi (Ando et al., 1999; Iijima et al.,
2000). Moreover, mature, phospho-APP was decreased in ev-
ery brain region analyzed in APPxBACE-H mice including the
corpus callosum and sciatic nerve (Fig. 6 B). This absence of
phospho-APP upon BACE overexpression suggests that APP
within post-Golgi compartments is greatly reduced.
To demonstrate that phospho-APP is selectively trans-
ported by fast anterograde axonal transport and that this pool of
APP is diminished upon BACE overexpression, we radiolabeled
retinal ganglion cells by intravitreal injections of [
32P]PO4 (Fig. 6
C) followed by immunoprecipitation of optic nerve lysates for
full-length APP. Radiolabeled phospho-APP was present within
optic nerves of APP Tg mice, whereas no radiolabeled APP was
Figure 4. BACE overexpression inhibits A 
amyloid formation. (A) Sections from APP or
APPxBACE (-L, -M, and -H) littermates (n   4
mice per genotype) were stained with thioflavin
S for fibrillar amyloid deposits. Sections are
from 14-mo-old mice, except for sections from
APPxBACE-H mice which are 16 mo old. To
corroborate thioflavin S staining, sections from
the cortex and hippocampus were stained
with NAB228. Bars: (top) 200  m; (middle)
100   m; (bottom) 200  m. (B–D) Amyloid
burden from sections (four sections/mouse) of
APP or APPxBACE (-L, -M, and -H) littermates
stained with NAB228 were analyzed by
quantitative image analysis (n    4 mice/
genotype). For the somatosensory cortex, the
percent area occupied by A  deposits (B,
ANOVA, P   0.05) and the number of A  de-
posits per section (C, ANOVA, P   0.0219)
are increased in APPxBACE-L mice relative to
APP mice (Bonferroni’s post-hoc relative to
APP, *P   0.05), whereas further increases in
BACE expression inhibited A  deposition. For
the hippocampus, the percent area occupied
by A  deposits (C, ANOVA, P   0.0099)
and the number of A  deposits per section (D,
ANOVA, P   0.0034) indicated that BACE ex-
pression decreased A  deposition in all three
BACE overexpressing lines. (Bonferroni’s post-
hoc relative to APP, *P   0.05, **P   0.01).JCB • VOLUME 168 • NUMBER 2 • 2005 296
detected in optic nerves of APPxBACE-H mice (Fig. 6 D). Im-
munoblotting of the same nitrocellulose membrane showed that
only fully glycosylated APP is phosphorylated, and that BACE
overexpression selectively reduced mature APP within the optic
nerve. Furthermore, the reduction in phospho-APP was specific
because 
32P-labeled middle molecular weight neurofilament sub-
unit (NFM) levels were not changed by BACE overexpression.
Decreased APP transport in APPxBACE 
mice
To further demonstrate that BACE overexpression resulted in a
shift in the subcellular site of  -cleavage, axonal transport within
sciatic nerves of APP or APPxBACE-H mice was interrupted by
ligation for 6 h (Fig. 7 A), after which segments of the sciatic
nerve proximal and distal to the ligature were assessed by immu-
noblotting for full-length APP, phospho-APP, and sAPP swe. In
monogenic APP mice, mature fully glycosylated APP isoforms
proximal to the ligature were  50% higher than in unligated sci-
atic nerves, whereas mature APP distal to the ligature was re-
duced by  60%, confirming that mature APP is subject to fast
axonal transport (Fig. 7 B). Immature APP levels were un-
changed after nerve ligation, suggesting that this signal is not de-
rived from axonally transported APP, which is consistent with
reports showing that the PrP promoter drives expression within
Schwann cells of the sciatic nerve (Follet et al., 2002). In APPx-
BACE-H mice, mature APP levels at steady-state in unligated
sciatic nerves were over fourfold lower relative to monogenic
APP mice. Furthermore, sciatic nerve ligation in APPxBACE-H
mice resulted in only a slight accumulation of mature APP. Sim-
ilar results were obtained when phospho-APP was immunopre-
cipitated by the PhAT antibody. Thus, BACE overexpression se-
lectively decreases the anterograde axonal transport of mature
phosphorylated isoforms of APP. Finally, to assess the amount
of   -cleavage within the axonal compartment, we measured
Figure 5. Quantification of A  accumulation
in APP and APPxBACE mice. Different brain
regions  were sequentially extracted in RIPA
buffer and 70% FA to obtain detergent-soluble
and insoluble fractions. A  was quantified by
Ban50-BA27/BC05 sandwich ELISA for full-
length A 40 and A 42. All mice were 14 mo
old except APPxBACE-H mice, which were 16
mo old. Quantification of soluble and insoluble
cortical A  (A and B) indicated that relative to
APP mice (n   3 females, 1 male), low BACE
expression (APPxBACE-L, n     3 females, 1
male) increased cortical A  accumulation,
whereas higher BACE expression inhibited A 
accumulation (APPxBACE-M, n   2 females, 1
male, and APPxBACE-H, n     2 females, 1
male). ANOVA yielded P   0.0006 and P  
0.0001 for soluble and insoluble cortical A 
measurements, respectively. Quantification of
soluble and insoluble hippocampal A  indi-
cated that hippocampal A  accumulation de-
creased in a dose-dependent manner due to
BACE overexpression (C and D). ANOVA
yielded P   0.0002 and 0.002 for soluble
and insoluble hippocampal A  measure-
ments, respectively. Both soluble and insoluble
A  from the cerebellum were low in all geno-
types (E and F). ANOVA failed to show any
significance for data from cerebellar A  mea-
surements. For cortical and hippocampal A 
measurements, Bonferroni’s post-test revealed
significant differences relative to APP mice
(*P   0.05, **P   0.01, ***P   0.001).PERIKARYAL BACE CLEAVAGE INHIBITS A  DEPOSITION • LEE ET AL. 297
sAPP swe levels proximal to the ligature in sciatic nerves of
APP mice. The decrease in sAPP swe produced within the
proximal segment of the sciatic nerve in APPxBACE-H mice
relative to APP mice (Fig. 7 B), coupled with the increase in
sAPP swe in total cortical lysates upon BACE overexpression
(Fig. 2 A) indicates that APP cleavage had shifted from an ax-
onal/synaptic compartment to the cell body.
Overexpression of both APP and BACE could potentially
result in aberrant trafficking of either protein. To rule out arti-
facts induced by APP overexpression, sciatic nerve ligations
were performed in non-Tg and monogenic BACE mice (Fig. 7 C).
Again, mature forms of endogenous APP accumulated proxi-
mal to the ligature in non-Tg mice, and the amount of mature
APP accumulation was greatly reduced upon BACE overex-
pression. Furthermore, to exclude the possibility that BACE
overexpression nonspecifically affects axonal transport in gen-
eral, a panel of proteins subject to fast and slow, anterograde
and retrograde transport were assessed. No differences under
steady-state conditions or upon ligation were noted in non-Tg
or BACE Tg mice for kinesin, synaptophysin, dynein, neurofil-
ament or  -tubulin. Therefore, the reduction in APP axonal
transport cannot be attributed to aberrant localization of the
overexpressed APP or to a nonspecific down-regulation of ax-
onal transport upon BACE overexpression.
Figure 6. Decreased mature, phospho-APP in APPxBACE axons. (A) Biochemical markers of APP trafficking in APP and APPxBACE mice. Cortical lysates
(n   2–5 per genotype) were immunoprecipitated with 5685 (phosphorylation-independent COOH-terminal APP antibody) or PhAT and probed with
NAB228 (anti-A 1-11, top) for C99 or with Karen (anti–NH2 terminus APP, bottom) for full-length APP. PhAT immunoprecipitations for full-length phospho-
APP were performed with 10 times the material relative to 5685 immunoprecipitations. An overexposure of the immunoblot for full-length APP is shown to
demonstrate the lack of immature APP in PhAT immunoprecipitates from APP mice, and the lack of phospho-APP in APPxBACE mice. (B) Regional analysis
of mature APP species. RIPA lysates from various regions from APP or APPxBACE-H mice (n   2 mice per genotype per region) were subject to immunopre-
cipitation with 5685 or PhAT followed by immunoblotting for full-length APP with Karen. White lines indicate that intervening lanes have been spliced out.
(C) Intravitreal injections of 
32P-labeled orthophosphate label retinal ganglion cells which send axonal projections via the optic nerve. 
32P-labeled APP
within the optic nerve is a measure of APP which has been phosphorylated and subject to anterograde axonal transport. (D) Transport of phospho-APP in
optic nerves. 6 h after intravitreal injection of [
32P]PO4, 
32P-labeled full-length APP was recovered by immunoprecipitation with 5685 from optic nerves
from APP mice, but not APPxBACE-H mice (7 and 15 mo old). Immunoblot of the same nitrocellulose membrane shows that 
32P-labeled APP comigrates
with only N- and O-glycosylated forms of APP, and that mature APP isoforms are depleted in optic nerves of APPxBACE-H mice. 
32P-labeled NFM levels,
assessed by immunoprecipitation with RMO26, were not affected by BACE overexpression. Three pairs of mice were analyzed and showed similar results.JCB • VOLUME 168 • NUMBER 2 • 2005 298
APP turnover and transport in Tg mice
To directly measure APP turnover in neuronal perikarya of
BACE mice, pulse-labeling studies were performed in spinal
cords and sciatic nerves. L5 spinal cord segments were injected
with [
35S]-methionine to label newly synthesized APP within
cell bodies of the spinal cord. After 30 min, no differences
were found in radiolabeled full-length APP in spinal cords of
non-Tg and BACE Tg mice indicating that APP synthesis is
unaltered by BACE overexpression (Fig. 8, A and B). How-
ever, by 8 h, APP levels were significantly reduced in APPx-
BACE mice indicating that increased BACE activity hastens
APP turnover. Significantly, N- and O-glycosylated APP was
conspicuously reduced in BACE mice when compared with
non-Tg mice at this time point. Furthermore, virtually no radio-
labeled APP was recovered from sciatic nerves of BACE Tg
mice, indicating once again that the rapid turnover of APP
within neuronal cell bodies of the spinal cord results in a dimi-
nution in axonal transport of APP (Fig. 8, A and C).
Discussion
Both the amount and type of A  produced are important for
AD pathogenesis. Thus, increased production of A  or in-
creased production of A 1-42 relative to A 1-40 can acceler-
ate the production of senile plaques and the development of
AD. In addition, the subcellular sites where A  is produced
may also play a role in AD pathogenesis. APP and the enzymes
that cleave it colocalize throughout the secretory pathway, and
A  can be produced at multiple intracellular sites. In neurons,
APP undergoes fast anterograde transport to nerve terminals
(Koo et al., 1990; Ferreira et al., 1993; Buxbaum et al., 1998),
and is metabolized into A  peptides that are released and de-
posited as amyloid plaques around nerve terminals (Lazarov et
al., 2002; Sheng et al., 2002). Thus, the axonal/synaptic frac-
tions of APP appear particularly important in the generation of
A  species that are ultimately deposited in amyloid plaques.
To further explore the relationships between the quantita-
tive, qualitative and spatial factors that influence A  produc-
tion and deposition, we produced Tg mice that expressed in-
creased levels of BACE. Surprisingly, an inverse relationship
between BACE expression and A  production/deposition was
found. Our efforts to understand this paradoxical result led us
to discover that BACE overexpression shifted the sites of APP
processing such that APP proteolysis occurred predominantly
in neuronal perikarya rather than in axons and axon terminals
(Fig. 9). This alteration of APP processing upon BACE overex-
pression, together with the reduction of A  accumulation, indi-
cates that A  generated proximally in neuronal perikarya has a
different fate than A  that is generated at or near the synapse.
Several lines of evidence were provided to demonstrate
the depletion of APP before axonal transport. First, BACE
overexpression reduced  -cleavage as seen by the reduction in
C83. Since our previous studies have shown that  -secretase
competes with BACE within the TGN (Skovronsky et al.,
2000), the reduction of C83 in APPxBACE mice suggests that
 -cleavage of APP is enhanced within the TGN. Second, N-
and O-glycosylated APP was reduced in BACE overexpressing
Figure 7. Decreased axonal transport and processing of APP in APPx-
BACE mice. (A) The sciatic nerve is a bundle of axons from sensory and
motor neurons present in the dorsal root ganglion or the spinal cord. Upon
ligation, proteins subject to anterograde axonal transport accumulate in the
nerve segment proximal to the ligature. (B) Transport and processing of APP
in ligated sciatic nerves. Sciatic nerves of APP or APPxBACE-H mice were
ligated for 6 h. 5-mm segments proximal and distal to the ligature were
homogenized,  corrected for protein concentration, and immunoprecipi-
tated with 5685 or PhAT. Segments from the unligated contralateral sciatic
nerve were processed in parallel. Immunoprecipitates were immunoblotted
with Karen for total full-length APP or full-length phospho-APP. Lysates were
subject to another round of immunoprecipitation with Karen, followed by
immunoblotting with 54 for sAPP swe. Because  -tubulin levels are un-
changed after 6 h of ligation, an immunoblot for  -tubulin is shown to dem-
onstrate equal loading. Four pairs of mice were analyzed and showed
similar results. (C) Endogenous APP axonal transport upon BACE overex-
pression. Sciatic nerves of non-Tg and monogenic BACE mice were ligated
for 6 h (n   3 pairs). Segments proximal and distal to the ligature were
assessed for full-length APP by immunoprecipitation with 5685 and immuno-
blotting with Karen. Lysates were pooled due to the low level of endoge-
nous APP within the sciatic nerve. Sciatic nerve from an APP mouse was run
in parallel as a molecular weight marker. Immunoblots for synaptophysin,
kinesin, dynein, NFL, and  -tubulin were also performed.PERIKARYAL BACE CLEAVAGE INHIBITS A  DEPOSITION • LEE ET AL. 299
mice indicating that APP is cleaved soon after carbohydrate
processing in the Golgi apparatus. Third, although BACE over-
expression increased C99 levels, the majority of C99 was not
phosphorylated. In contrast, at least 50% of C99 was phosphor-
ylated in monogenic APP mice. Because phosphorylation of
threonine 668 of APP is a posttranslational modification found
selectively within neuronal growth cones and neurites (Ando et
al., 1999; Iijima et al., 2000), the lack of phospho-C99 indi-
cates that APP cleavage in APPxBACE mice occurs in early
compartments. Fourth, although mature full-length phospho-
APP was readily detected from the corpus callosum, sciatic
nerves and optic nerves of APP mice, almost no mature, phos-
pho-APP was detected in APPxBACE bigenic mice demon-
strating that APP was present only at very low levels in ax-
ons. Fifth, 
32P-labeled APP was dramatically reduced in optic
nerves upon BACE overexpression, indicating that  -cleavage
occurs before the phosphorylation and anterograde axonal
transport of APP. Sixth, the reduction of APP accumulation
upon sciatic nerve ligation supports the hypothesis that little in-
tact APP is transported into axons in APPxBACE mice. Fi-
nally, pulse-labeling of spinal cords demonstrated that BACE
overexpression increases APP turnover such that APP is not
available for axonal transport. Notably, BACE overexpression
did not alter APP synthesis, nor levels of immature ER-resident
APP suggesting that APP cleavage is occurring within the
Golgi after transit from the ER. Based on the evidence pre-
sented above, we concluded that BACE overexpression in-
creases   -cleavage in proximal subcellular compartments,
most likely within the Golgi apparatus, at the expense of axonal
and synaptic APP (Fig. 9).
Despite increased  -cleavage, as evidenced by increased
sAPP , sAPP  , sAPP swe, and C99 levels in APPxBACE
mice, A  levels were reduced by high BACE expression. This
finding is contrary to cell culture models in which BACE over-
expression leads to increased secretion of A  (Liu et al., 2002;
E.B. Lee et al., 2003). One potential explanation of our results is
that the fate of A  produced in neuronal perikarya and axonal
terminals in the in vivo brain are different. For example, the mi-
croenvironment wherein A  is secreted may influence A  de-
position. Synaptic zinc has been shown to play a role in A  ag-
gregation and deposition, and depletion of synaptic zinc inhibits
amyloid formation in vivo (Lee et al., 2002) suggesting that the
environment within synaptic vesicles or the microenvironment
at synaptic terminals is crucial to A  amyloidogenesis.
Alternatively, the differential fates of A  may be related
to the localization of A  degrading activities in brain. Nepri-
lysin is found predominantly in synapses and axons of smaller
interneurons (Fukami et al., 2002). The localization and enzy-
matic properties of neprilysin are consistent with A  degrading
activity within secretory vesicles and the plasma membrane
(Iwata et al., 2000). In contrast, endothelin-converting enzyme
is likely to degrade intracellular A  within acidic organelles
such as the TGN (Schweizer et al., 1997; Eckman et al., 2001).
Finally, cell surface and secreted forms of insulin-degrading
enzyme (IDE) have been implicated in A  catabolism (Qiu et
al., 1998; Vekrellis et al., 2000). Genetic ablation of IDE re-
sults in accumulation of unphosphorylated APP fragments
without altering phosphorylated fragments, suggesting that
IDE activity is localized predominantly near the cell soma
(Farris et al., 2003). All three of these enzymes have been
shown to influence steady-state levels of A  in vivo, and may
serve complimentary roles in A  catabolism (Iwata et al.,
2001; Eckman et al., 2003; Farris et al., 2003; Miller et al.,
2003). Thus, altering the subcellular localization of  -cleavage
may disrupt the normal catabolic pathways of A , thereby ac-
counting for the different fates of somatic and synaptic A .
In support of the view that the ability of certain A  pep-
tides to deposit into amyloid plaques is related to their sus-
ceptibility to degradation, A  peptides of different lengths
were differentially affected by BACE overexpression. The
rate-limiting step of A  degradation in vivo is the production
of A 10-37 (Iwata et al., 2000), suggesting that NH2-terminal
truncations may render A  peptides more prone to degrada-
tion. We found that minimal amounts of the NH2-terminally
Figure 8. Kinetic APP analysis of the spinal
cord and sciatic nerve. L5 segments of non-Tg
and BACE Tg spinal cords were injected with
[
35S]-methionine and analyzed at 0.5, 8, and
16 h after injection. (A) Full-length APP from
spinal cords and sciatic nerves was immuno-
precipitated with 5685 and electrophoresed
on 7.5% Tris-glycine gels to examine the turn-
over of APP in vivo. Despite differences in APP
levels, general radiolabeling of proteins is sim-
ilar between non-Tg and BACE Tg mice, as
determined by electrophoresis and autora-
diography of immunoprecipitation supernatants.
(B and C) Quantification of radiolabeled APP
in spinal cords and sciatic nerves (n   3 non-
Tg, 2 BACE-H and 1 BACE-M per time point)
demonstrated significantly lower levels of APP
in both spinal cords and sciatic nerves (*P  
0.05, ***P    0.0001), indicating that in-
creased perikaryal APP proteolysis depletes
mature, axonally transported APP.JCB • VOLUME 168 • NUMBER 2 • 2005 300
truncated A 11-40/42 peptide could be detected upon BACE
overexpression despite the increase in C89 levels, supporting
the hypothesis that this NH2-terminal truncated variant is eas-
ily degraded in vivo.
In APPxBACE bigenic mice overexpressing the lowest
levels of BACE, we observed an increase in A  deposition in
neocortex, supporting the idea that slight elevations in BACE
expression and activity may facilitate the development of AD
(Fukumoto et al., 2002; Holsinger et al., 2002). Furthermore,
lower levels of BACE overexpression than those reported here
increase steady-state A  levels in Tg mice (Bodendorf et al.,
2002). Nonetheless, the effects of BACE overexpression were
not specific to APP harboring the Swedish mutation as BACE
overexpression resulted in similar reductions of endogenous
and exogenous mature APP in non-Tg mice, APP I Tg mice,
and human NTera2 cells (Fig. S2, available at http://www.
jcb.org/cgi/content/full/jcb.200407070/DC1).
Regardless of the expression level, A  deposition was
inhibited in the hippocampus. Even at 20 mo old when APPx-
BACE-M mice accumulate a large amount of brain A 
deposits, hippocampal A  deposits are markedly reduced
(Fig. S3, available at http://www.jcb.org/cgi/content/full/jcb.
200407070/DC1). We postulate that the region-specific ef-
fects of BACE overexpression on A  pathology are related to
qualitative or quantitative differences in metabolic pathways
for APP intrinsic to specific subsets of neurons. For example,
mild increases in BACE activity may increase synaptic A  in
smaller cortical interneurons with relatively short axonal pro-
cesses. However, due to the length of both the perforant path-
way and the mossy fiber pathway, slight elevations in peri-
karyal BACE activity may preclude synaptic processing of
APP in the hippocampus.
Similar region-specific amyloid plaque formation has
been observed in the brain of AD patients. For example,
whereas association cortices and the limbic system are prone to
A  amyloid, other regions such as primary sensory/motor neo-
cortices, striatum, brainstem, and spinal cord are relatively un-
affected (Braak and Braak, 1991) despite the widespread ex-
pression of APP (Tanzi et al., 1987). Interestingly, we found
that layer IV neurons within regions of the mouse somatosen-
sory cortex were spared from A  pathology in both APP and
APPxBACE-M mice (Fig. S3). These layer IV neurons receive
a large proportion of their synaptic input from spatially distant
thalamic neurons. Although speculative at this point, our re-
sults suggest that distinct subsets of neurons and/or the length
and number of their efferent inputs may be significant factors
that in part determine the regional differences in amyloid pa-
thology found in AD.
In conclusion, although the reduction of A  deposition
upon BACE overexpression was unexpected, our finding that
synaptic A  is crucial to the development of amyloid plaques
offers several new avenues of research that may improve our
understanding of the pathogenesis of amyloid plaques. Thus,
further progress toward understanding APP transport, A  ag-
gregation within axonal or synaptic vesicles, and the distribu-
tion of A  degrading enzymes may yield insights which may
prove to be clinically relevant.
Figure 9. Subcellular processing of APP and the development of A 
amyloid pathology. In monogenic APP mice (red), APP is synthesized in
the ER and trafficked to the Golgi apparatus acquiring N- and O-linked
oligosaccharides within these organelles. APP is targeted for fast antero-
grade axonal transport, coincident with phosphorylation of the COOH
terminus of APP. A high proportion of  -cleavage occurs distally within
an axonal or synaptic compartment where the likelihood of A  degrada-
tion diminishes in favor of A  secretion and aggregation. BACE overex-
pression increases  -cleavage such that little APP is targeted to the axon
(green) which precludes synaptic targeting and release of A . The inhi-
bition of A  pathology due to BACE overexpression indicates that the
subcellular localization of A  either alters the aggregation kinetics of
A , or alters the stability of the peptide due to the intracellular or extra-
cellular localization of A  degrading enzymes. A  secreted in the soma-
todendritic compartment (boxes) remains soluble, whereas that released
from synaptic terminals (star bursts) deposits into plaques. Red and
green circles indicate transported APP in monogenic APP and bigenic
APPxBACE mice.PERIKARYAL BACE CLEAVAGE INHIBITS A  DEPOSITION • LEE ET AL. 301
Materials and methods
Generation of Tg mice
The human BACE cDNA was cloned into the MoPrP.Xho expression vector
(Borchelt et al., 1996) at the XhoI restriction site to generate a 15.9-kb
NotI linear fragment. DNA was microinjected into C57B6/C3H mouse
eggs by the Tg and Chimeric Mouse Facility of the University of Pennsylva-
nia. Genomic DNA was used to identify founders by DNA hybridization
of slot blots with 
32P-labeled oligonucelotide probes generated from a
BACE cDNA PstI digest template. To generate bigenic mice, APP mice
(Hsiao et al., 1996) were crossed with BACE Tg lines to generate double
heterozygous offspring.
Immunoprecipitation and Western blot analysis
Proteins were extracted by homogenization of tissue in RIPA buffer (0.5%
sodium deoxycholate, 0.1% SDS, 1% NP-40, 5 mM EDTA in TBS, pH 8.0)
containing protease inhibitors (1  g/ml of pepstatin A, leupeptin, L-1-tosyl-
amido-2-phenylethyl chloromethyl ketone, 1-chloro-3-tosylamido-7-amino-
2-heptanone, soybean trypsin inhibitor, and 0.5 mM PMSF) followed by
centrifugation at 100,000 g for 20 min at 4 C. When indicated, immuno-
precipitations were performed before electrophoresis on either Tris-glycine
or 10/16% step-gradient Tris-tricine gels, followed by immunoblotting
with the antibodies listed in Table S1, available at http://www.jcb.org/
cgi/content/full/jcb.200407070/DC1. For quantification of BACE, se-
rial dilutions of brain lysates were performed to obtain results within
the linear range of quantification. For dephosphorylation experiments,
COOH-terminal fragments immunoprecipitated with 5685 were treated
with E. coli alkaline phosphatase at 37 C before electrophoresis.
Sandwich ELISA analysis
Brain regions were sonicated in RIPA buffer (1 ml/150 mg tissue) contain-
ing protease inhibitors and centrifuged at 100,000 g for 20 min at 4 C.
The pellet was sonicated in 70% FA (2  l/mg tissue) followed by a sec-
ond of centrifugation. Both RIPA and FA lysates were assayed by sand-
wich ELISA as previously described (E.B. Lee et al., 2003). Ban50 (anti–
A 1-10) was used to capture full-length A , whereas BC05 and BA27 were
used to detect A 40 and A 42, respectively. To determine the relative con-
tent of NH2-terminally truncated A , ELISA plates were coated with either
JRF/c40 or JRF/c42 to capture A 40 and A 42, respectively. The concen-
trations of full-length A  versus total A  were determined by using JRF/
A N (anti-A 1-7) or m266 (anti-A 13-28) as reporting antibodies.
Histology and immunohistochemistry
Mouse brains were fixed in either ethanol or 4% neutral-buffered formalin
for 24 h. Samples were dehydrated through a series of graded ethanol solu-
tions to xylene and infiltrated with paraffin as described previously (Trojan-
owski et al., 1989). Tissue sections (6  m) were stained using standard avi-
din-biotin-peroxidase methods using 3–3  DAB. BaceN1 (rabbit anti–NH2
terminus of BACE; Huse et al., 2000), NAB228 (mouse anti-A 1-11), 4G8
(mouse anti-A 17-24), m11 (mouse anti-A free11-x) and 82 (rabbit anti-A pyro11-x)
were used as primary antibodies. Thioflavin S staining was used to detect
fibrillar A  deposits, using Vectashield mounting medium (Vector Laborato-
ries). Images were obtained using 1.25-40 /0.16-0.85 objectives on a mi-
croscope (model BX51; Olympus) with a ProgRes C14 Jenoptik camera and
software (Laser Optik Systeme). For quantitative image analysis, sections of
the somatosensory cortex and hippocampus were stained with NAB228
and analyzed using Image Pro-plus (Media Cybernetics, Inc.).
32P-labeling of phospho-APP
Intravitreal injections of 
32P-labeled orthophosphate (250  Ci/2  l per
eye; PerkinElmer) were performed on three pairs of anesthetized APP and
APPxBACE-H mice. 6 h after injection, optic nerves were homogenized in
RIPA buffer containing protease inhibitors and phosphatase inhibitors (50
mM sodium fluoride and 0.2 mM sodium vanadate), immunoprecipitated
with 5685 for full-length APP or RMO26 for NFM (Black and Lee, 1988),
separated on a 7.5% Tris-glycine gel, transferred to a nitrocellulose mem-
brane, and exposed to a phosphorimager screen. The same membrane
was then immunoblotted with an NH2-terminal APP antibody (Karen).
Sciatic nerve ligation
Mice were anesthetized and one sciatic nerve from each mouse was li-
gated approximately in the middle. The other sciatic nerve was used as an
unligated control. 6 h after ligation, 5-mm sciatic nerve segments proximal
and distal to the ligature were sonicated in RIPA buffer containing pro-
tease inhibitors and centrifuged at 100,000 g for 20 min at 4 C. Proteins
were analyzed by immunoblotting using the antibodies listed in Table S1.
Full-length APP, phospho-APP and sAPP swe were immunoprecipitated
with 5685 before immunoblotting.
Spinal cord pulse-labeling
L5 segments of spinal cords from non-Tg and BACE Tg mice were injected
with 250  Ci/0.71  l of [
35S]-methionine (PerkinElmer) bilaterally at an
infusion rate of 0.1  l/min. Mice were killed at 0.5, 8, and 16 h after in-
jection when sciatic nerves and spinal cord segments 2-mm rostral and
caudal to the injection site were harvested. Samples were homogenized
with RIPA buffer, immunoprecipitated with 5685 for full-length APP, and
electrophoresed on 7.5% Tris-glycine gels. Radiolabeled APP was quanti-
fied by ImageQuant phosphorimager analysis (Molecular Dynamics).
Online supplemental material
Table S1 lists the antibodies used for biochemical analysis. Fig. S1 shows
immunohistochemical and biochemical analysis of full-length and trun-
cated A  in aged Tg mice. Fig. S2 shows the reduction of mature APP in
APP I Tg mice and human neuronal cultures upon BACE overexpression.
Fig. S3 shows the regional distribution of amyloid pathology in 20-mo-old
Tg mice. Online supplemental material is available at http://www.jcb.org/
cgi/content/full/jcb.200407070/DC1.
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